AstriVax

Ambachtenlaan 1

Heverlee 3001

BE

AstriVax

Foundation date

30/06/2022

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first-in-class Plug & Play vaccine platform with a patented DNA-based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.

Upcoming events

Latest news

  • Celyad Oncology appoints Georges Rawadi as its new CEO

    Tuesday March 28th 2023

  • BioLizard appoints Paul Vauterin as Chief Technology Officer

    Monday March 27th 2023

  • ImmuneWatch receives Antwerp Innovation grant to accelerate vaccine development with AI

    Monday March 27th 2023

Jobs by AstriVax